Clinical Trial Update: Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy results for mipomersen in high-risk statin-intolerant patients. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Kynamro (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Metabolic Diseases, Hyperlipidemias | Phase 2 | Status: COMPLETED | Results posted: 2013-04-05